Skip to main content
SpringerLink
Log in

Mammakarzinom

  • Chapter
Therapiekonzepte Onkologie

  • 31 Accesses

Zusammenfassung

Acht verschiedene histologische Entitäten werden beschrieben: invasiv duktal (53%), medullär (6%), invasiv lobulär (5%), mucinös (2,5%), tubulär (1,2%), adenoid-cystisch (0,4%), papillär (0,3%), Karzinosarkom (0,1%). Nicht-invasive Varianten machen einen ansteigenden Anteil der neudiagnostizierten Mammakarzinome aus. Ein Drittel aller Mammakarzinome zeigt eine Mischhistologie. Ferner gibt es primäre Malignome der Brust, die sich nicht aus Brustdrüsengewebe entwickeln, zum Beispiel maligne Lymphome und Sarkome.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Miller AB (1991) Causes of breast cancer and high-risk groups. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast diseases. Second edition. Lippincott, Philadelphia, pp 119–126

    Google Scholar 

  2. Kelsey JL, Gammon MD (1991) The epidemiology of breast cancer. CA 41: 146–165

    PubMed  CAS  Google Scholar 

  3. NCI (1992) Cancer statistics review 1973–1989. September

    Google Scholar 

  4. Rosen PP (1991) The pathology of invasive breast carcinoma. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast diseases. Second edition. Lippincott, Philadelphia, pp 245–296

    Google Scholar 

  5. Fisher ER, Gregorio RM, Fisher B (1975) The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer 36: 1–84

    Article  PubMed  CAS  Google Scholar 

  6. Breast-Chapter 23 (1988) In: Beahrs OH, Henson DE, Huffer RVP, Myers MH (eds) Manual for staging of cancer. Third edition. Lippincott, Philadelphia, pp 145–150

    Google Scholar 

  7. Broder LE, Tormey DC (1974) Combination chemotherapy of carcinoma of the breast. Cancer Treat Rev 1: 183–203

    Article  Google Scholar 

  8. Henderson IC (1991) Chemotherapy for metastatic disease. In: Harris JR, Hellman S et al. (eds) Second edition breast diseases. Lippincott, Philadelphia, pp 604–665

    Google Scholar 

  9. Hortobagyi GN (1992) Overview of new treatments for breast cancer. Br Cancer Res Treat 21: 3–13

    Article  CAS  Google Scholar 

  10. Rubens RD, Knight RK, Hayward JL (1978) Chemotherapy of advanced breast cancer: A controlled randomized rial of cyclophosphamide vs a four-drug combination. Br J Cancer 32: 730–735

    Google Scholar 

  11. Canellos GP, DeVita VT, Gold GL et al. (1976) Combination chemotherapy for advanced breast cancer: Response and effect on survival. Ann Intern Med 84: 389–392

    Google Scholar 

  12. Mouridsen HT, Palshof T, Brahm M et al. (1972) Evaluation of single versus multiple-drug chemotherapy in the treatment of advanced breast cancer. Cancer Treat Rep 61: 47–50

    Google Scholar 

  13. Lemkin SR, Dollinger MR (1973) Combination vs. single drug therapy in advanced breast cancer. Proc Amer Assoc Cancer Res 7: 41

    Google Scholar 

  14. Chlebowski RT, Irwin LE, Pugh RP et al. (1979) Survival of patients with metastatic breast cancer treated with either combination or sequential chemotherapy. Cancer Res 39: 4503–4506

    PubMed  CAS  Google Scholar 

  15. Hoogstraten 8, George SL, Samal B et al. (1976) Combination chemotherapy and adriamycin in patients with advanced breast cancer. Cancer 38: 13–20

    Article  PubMed  CAS  Google Scholar 

  16. Bull JM, Tormey DC, Li S-H et al. (1978) A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41: 1649–1657

    Article  PubMed  CAS  Google Scholar 

  17. Smalley RV, Carpenter J, Bartolucci A et al. (1977) A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone ( CMFVP) in patients with metastatic breast cancer. Cancer 40: 625–632

    Google Scholar 

  18. Muss HB, White DR, Richards F et al. (1978) Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer. Cancer 42: 2141–2148

    Article  PubMed  CAS  Google Scholar 

  19. Tormey DC, Cortes E, Weinberg VE et al. (1984) A comparison of intermittent vs continuous and of adriamycin vs methotrexate 5-drug chemotherapy for advanced breast cancer. J Clin Oncol 7: 231–239

    Article  CAS  Google Scholar 

  20. Aisner J, Weinberg V, Perloff M et al. (1987) Chemotherapy versus Chemoimmunotherapy (CAF v CAFVP v CMF Each ± MER) for metastatic carcinoma of the breast: A CALGB Study. J Clin Oncol 5: 1523–1533

    Google Scholar 

  21. Brincker H, Rose C, van de Maase H et al. (1984) A randomized study of CAF + TAM versus CMF + TAM in metastatic breast cancer. Proc Am Soc Clin Oncol 3: 113 (abst)

    Google Scholar 

  22. Kolaric K, Nola P, Roth A et al. (1977) The value of adriamycin in combination chemotherapy of metastatic breast cancer–A comparative study. Libri Oncol 6: 5–10

    Google Scholar 

  23. Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of Early Breast Cancer by hormonal, cytotoxic, or immune therapy. The Lancet 339:1–15, 71–85

    Google Scholar 

  24. NIH Consensus Conference (1991) Treatment of early-stage breast cancer. JAMA 265: 391–395

    Article  Google Scholar 

  25. Glick JH, Gelber RD, Goldhirsch A, Senn HJ (1992) Adjuvant therapy of primary breast cancer. 4th International conference on adjuvant therapy of primary breast cancer. J Natl Cancer Inst 84: 1479–1485

    Article  PubMed  CAS  Google Scholar 

  26. Hortobagyi GN, Buzdar AU (1991) Locally advanced breast cancer: A review including the MD Anderson Experience. In: Ragaz J, Mel IM (eds) High-risk breast cancer. Springer, Berlin, pp 382–415

    Chapter  Google Scholar 

  27. Henderson IC (1991) Endrocrine therapy of metastatic breast cancer. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast diseases. Second edition. Lippincott, Philadelphia, pp 559–603

    Google Scholar 

  28. Buzdar AU (1990) Current status of endocrine treatment of carcinoma of the breast. Sem Surg Oncol 6: 77–82

    Article  CAS  Google Scholar 

Download references

Authors
  1. G. N. Hortobagyi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung), Westdeutsches Tumorzentrum Essen, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    Siegfried Seeber  & Jochen Schütte  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Hortobagyi, G.N. (1993). Mammakarzinom. In: Seeber, S., Schütte, J. (eds) Therapiekonzepte Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10495-8_42

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10495-8_42

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-56872-8

  • Online ISBN: 978-3-662-10495-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation